Buoyed by the progress it has made with its lead integrin therapy for moderate to severe ulcerative colitis, MORF-057, which significantly reduced disease activity in a phase IIa trial, Morphic Therapeutic Inc. is raising $240 million in a public offering to further advance the candidate through the clinic.
The proportion of clinical data focused on COVID-19 therapeutics and vaccines has dropped from 21.3% in 2020 at the height of the pandemic to only 7.7% for 2022.
Nearing the end of 2022, the COVID-19 pandemic clearly no longer dominates the clinical activity reported by biopharma companies. Overall clinical data tracked by BioWorld is down significantly, as is the proportion focused on the SARS-Cov-2 virus. Therapeutics and vaccines targeting cancer, infectious diseases and neurological disorders, however, remain a stronghold.
Nearing the end of 2022, the COVID-19 pandemic clearly no longer dominates the clinical activity reported by biopharma companies. Overall clinical data tracked by BioWorld is down significantly, as is the proportion focused on the SARS-Cov-2 virus. Therapeutics and vaccines targeting cancer, infectious diseases and neurological disorders, however, remain a stronghold.
Shares in Inventiva SA (Paris:IVAA) fell about 18% after development partner Abbvie Inc. quit development of the inflammatory disease drug cedirogant following an unfavorable readout from a phase II toxicology study. The companies had worked on the asset together for about a decade. Inventiva emerged from Abbott in 2012, before the healthcare giant split in 2013 to form pharma specialist Abbvie and Abbott Laboratories, focused on medical devices.
Clinical data through the last week of October 2022 has dropped 17% in comparison with 2021. So far in 2022, there have been a total of 2,812 phase I, II and III clinical entries, compared with 3,389 during the first 10 months of 2021.
The amount of clinical news in 2022 continues to lag last year, partly due to a decline in COVID-19-related data. Through the last week of September, there have been a total of 2,495 phase I, II and III clinical entries, compared with 3,027 during the first three quarters of 2021. This represents a drop in activity of 17.6%.
With financings, U.S. FDA approvals and mergers and acquisitions all tracking behind last year, why would clinical data be any different? According to BioWorld research, clinical trial reports are down by 16.2% this year. The number of efforts targeting the COVID-19 pandemic, as well as the proportion of data focused on infectious diseases, are also dropping.
The volume of clinical data in 2022 is down by 16.9% from last year. Pandemic efforts are still decreasing while three therapeutic areas dominate the news. Through the last week of July, there have been a total of 1,997 clinical entries, compared with 2,402 by this point in 2021.
Clinical data readouts in 2022 have fallen by 14.8% in comparison with the same timeframe last year, and more than half of all reports are for drugs and biologics targeting three major therapeutic areas. In the first six months of the year, there have been 1,707 clinical entries, compared with 2,004 last year.
